Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma
ConclusionA maximum tolerated dose of pimasertib 45 mg BID was established in Japanese patients with ST, but not established in patients with HCC. The global RP2D of 60 mg BID was not confirmed in Japanese patients. Pimasertib monotherapy in unselected patients with ST may not warrant further investigation; Part 2 was not conducted.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Hepatocellular Carcinoma | Japan Health | Liver Cancer | Oral Cancer | Study | Toxicology | Vitamin A